Sh­iono­gi, BioVer­sys team up on an­tibi­otics for lung dis­ease in deal worth up to $614M

BioVer­sys is en­ter­ing a pact with Sh­iono­gi to ad­vance the Swiss biotech’s an­tibi­ot­ic pro­gram tar­get­ing non-tu­ber­cu­lous my­cobac­te­ria, with over half a bil­lion dol­lars in biobucks …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER